

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No. 91120000103100784F)

(Incorporated in the People's Republic of China)

Resolutions Passed at the 4th Board Meeting for FY2017

The board of directors (the "Board") and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "**Company**") had on 5 May 2017 issued a notice of board meeting to its directors in respect of the 4th board meeting for FY2017, and the board meeting was duly convened on 15 May 2017. The following resolution was discussed and passed by the 7 directors out of the full board of 9 directors, with Mr. Ma Gui Zhong and Mr. Zhang Jian Jin being absent.

The said meeting was convened in compliance with the applicable Companies law, Securities Law and the Articles of Association of the Company, and the following resolutions were passed:

1. That, the re-appointment of "Ruihua Certified Public Accountants LLP" as PRC auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company, and re-appointment of "RSM Chio Lim LLP" as international auditors of the Company to hold office until the conclusion of the next annual general meeting of the Company, and the authorization to the Board to determine their remuneration be approved;
2. That, the proposed provision of corporate guarantee in relation to the credit facility for an aggregate amount of up to RMB10,400,000 to one of the Company's subsidiaries, Chengdu Zhong Xin Pharmaceuticals Co., Ltd be approved;
3. That, the proposed scheme on return of investment to shareholders from 2017 to 2019 be approved.
4. That, the proposed convening of the first Extraordinary General Meeting in 2017 be approved.

The above resolutions No. 1, No. 2 and No.3 shall be tabled at the first Extraordinary General Meeting in 2017 to be convened for shareholders' approval.

By order of the Board
15 May 2017